News

CaringKind, New York’s leading organization in caring for Alzheimer’s disease and dementia patients for the past 30 years, has established an alliance with Cure Alzheimer’s Fund, a not-for-profit organization funding research to prevent, stop, or reverse the neurodegenerative disease. With the new alliance, people who contact CaringKind to find…

Quest Diagnostics has announced the release of CogniSense, its digital cognitive assessment tool to assist physicians in diagnosing, assessing, and managing the care of people with cognitive dysfunction. Quest says its design objective for CogniSense was to overcome the various limitations inherent in conventional, paper-based cognitive assessment, such as…

Researchers at Genentech discovered that antibodies against tau — a protein creating toxic tangles inside nerve cells of people with Alzheimer’s disease — protect from tau toxicity only when antibodies don’t engage inflammation-triggering microglial cells to get rid of the protein. The findings, published in the journal Cell…

Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain…

Researchers at the Technical University of Madrid, in Spain, have discovered that changes in nerve signaling patterns exist in the brains of people with mild cognitive impairment, a condition believed to precede Alzheimer’s disease and other dementias. From the study  ”A multicenter study of the early detection of synaptic…

In mid-July, scientists at the Washington University Medical School, Saint Louis, published a study that inspired awe in fellow researchers — an updated map of the cerebral cortex of the human brain, identifying nearly 100 new areas. The exceedingly intricate and updated map, published in the journal Nature…

Data from a Phase 2b clinical trial showing that  vTv Therapeutics‘s investigational drug, azeliragon, slows cognitive decline in patients with mild Alzheimer’s disease were presented at the Alzheimer’s Association International Conference 2016 in Toronto this week. Azeliragon is a drug that blocks the receptor RAGE (Receptor for Advanced Glycation Endproducts) in…

On July 26, a different kind of happening interrupted the usual bustle of activity at this year’s Alzheimer’s Association International Conference (AAIC 2016) in Canada. Attending scientists became the first viewers (at a sneak-peek preview before the North American premiere) of a new kind of full-length documentary film — one that reveals untold…

Researchers at the University of Sussex in England have built a protein closely resembling amyloid-β, except for the fact that it is not capable of aggregating. The new protein, described in a report titled, “A critical role for the self-assembly of Amyloid-β1-42 in neurodegeneration,“ published in the…

Each year on World Brain Day, July 22 the year, the World Federation of Neurology (WFN) dedicates a brain awareness campaign to a different topic. Tomorrow’s will draw our attention to the aging brain — and the diseases that damage it. The campaign hopes to be a wake-up call for politicians and…